We are live on ! Find out more
DCOY

Decoy Therapeutics
DCOY

1 hedge funds and large institutions have $1.07M invested in Decoy Therapeutics in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

68% less capital invested

Capital invested by funds: $3.33M → $1.07M (-$2.26M)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$580K

Top Sellers

Rank Fund Capital Flow
1
Primecap Management
Primecap Management
California
-$1.16M
2
RA
Royce & Associates
New York
-$248K
3
BCM
Bridgeway Capital Management
Texas
-$47K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$32K
5
TSS
Two Sigma Securities
New York
-$13K

DCOY Hedge Fund Activity: Q3 2018 in Review

1 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2018, worth a combined $1.07M — down 68% from $3.33M a quarter earlier.

Fund positioning in DCOY was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $580K. The largest seller was Primecap Management, exiting entirely with an estimated $1.16M sold.

  • 1 institutional investor held Decoy Therapeutics (DCOY) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $1.07M of Decoy Therapeutics stock for Q3 2018, down 68% quarter-over-quarter.
  • 1 fund opened new Decoy Therapeutics positions in Q3 2018 and 1 closed out, a net change of 0 holders.
  • The largest Decoy Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $580K added.
  • The largest Decoy Therapeutics seller in Q3 2018 was Primecap Management, an estimated $1.16M sold.

Based on aggregated 13F filings for Q3 2018.